Mouth Dissolving Mosapride Tables Enhance Post Cesarean Gut Recovery
NCT ID: NCT03477266
Last Updated: 2018-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
400 participants
INTERVENTIONAL
2018-04-01
2018-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Timing of Midazolam Administration on Incidence of Postoperative Nausea and Vomiting
NCT05057767
Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting
NCT04013386
Intrathecal Atropine to Prevent Postoperative Nausea and Vomiting
NCT03387956
Granisetron Versus Metoclopramide Effects on Gastric Volume by Sonographic Assessment on Patients Undergoing Caesarean Section.
NCT04290026
Gastric Emptying With Metoclopramide in GLP-1 Agonist Patients Undergoing Elective Surgery
NCT07100691
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mouth dissolving mosapride
Fluxopride 5mg of Macryrl egypt 2 tablets one day before and immediately after elective cesarean section every 8hour for maximum of 5 days
Mosapride
Intake mouthly dissolving mosapride tablets in immediate post cesarean section
Placebo mouth dissolving tablets
Dummy identical tablets taken in the same way
Placebo Oral Tablet
Dummy identical tablets to mouthly dissolving mosapride tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mosapride
Intake mouthly dissolving mosapride tablets in immediate post cesarean section
Placebo Oral Tablet
Dummy identical tablets to mouthly dissolving mosapride tablets
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ashraf nassif mahmoud elmantwe,MD
Assistant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ashraf N Elmantwe, MD
Role: PRINCIPAL_INVESTIGATOR
Benha University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ashraf nassif Elmantwe
Banhā, Elqalopia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.